Skybiotech Healthcare (BOM:512036) Interest Expense: ₹-0.18 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:512036 Skybiotech Healthcare Ltd BOM:512036
24 GF Score
Price ₹124.20
! 5 Warning Signs
View Full Analysis

What is Skybiotech Healthcare Interest Expense?

Skybiotech Healthcare BOM:512036 +0.16% 24 Interest Expense is ₹-0.18 Mil as of Jun. 2026. GuruFocus rates BOM:512036 with a GF Score™ of 24/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Skybiotech Healthcare's interest expense for the three months ended in Jun. 2026 was ₹ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-0.18 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Skybiotech Healthcare's Operating Income for the three months ended in Jun. 2026 was ₹ -6.31 Mil. Skybiotech Healthcare's Interest Expense for the three months ended in Jun. 2026 was ₹ -0.04 Mil. Skybiotech Healthcare did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Skybiotech Healthcare  (BOM:512036) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Skybiotech Healthcare's Interest Expense for the three months ended in Jun. 2026 was ₹-0.04 Mil. Its Operating Income for the three months ended in Jun. 2026 was ₹-6.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ₹0.00 Mil.

Skybiotech Healthcare's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Skybiotech Healthcare did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Skybiotech Healthcare Interest Expense Historical Data

* Premium members only.

The historical data trend for Skybiotech Healthcare's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skybiotech Healthcare Interest Expense Chart

Skybiotech Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.94 -0.12 -0.21

Skybiotech Healthcare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.05 -0.04 -0.05 -0.04
BOM:512036
24GF Score
Skybiotech Healthcare Ltd BOM:512036
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skybiotech Healthcare Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-0.18 Mil mean?
Skybiotech Healthcare (BOM:512036) has a Interest Expense of ₹-0.18 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Skybiotech Healthcare and its competitors.
Is Skybiotech Healthcare's Interest Expense too high?
Skybiotech Healthcare's current Interest Expense is ₹-0.18 Mil. Overall, Skybiotech Healthcare has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Skybiotech Healthcare's Interest Expense compare to MMM and HON?
Skybiotech Healthcare's Interest Expense of ₹-0.18 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Conglomerates company?
A good Interest Expense depends on the Conglomerates industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Skybiotech Healthcare and its competitors. Skybiotech Healthcare's current Interest Expense is ₹-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skybiotech Healthcare stock overvalued right now?
Skybiotech Healthcare (BOM:512036) has a current Interest Expense of ₹-0.18 Mil. The current Interest Expense is ₹-0.18 Mil. Skybiotech Healthcare's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Skybiotech Healthcare (BOM:512036), the current Interest Expense is ₹-0.18 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skybiotech Healthcare Business Description

Address Paithan Road, Gevrai Tanda, Gut No. 05, Chhatrapati Sambhaji Nagar, MH, IND, 431002
Skybiotech Healthcare Ltd, formerly Kapil Cotex Ltd is engaged in textiles and allied products, including dyeing, printing, spinning, weaving, and manufacturing fabrics from raw cotton. During the year under review, the company has not generated any revenue from its core business activities. Instead, it earned income from consultancy services for foreign clients and from investments in shares, generating capital gains and dividends. The company's current revenue mainly comes from these non-core activities rather than textile manufacturing.
24GF Score

Get the complete analysis for BOM:512036

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.20
Price